| Japanese |
|---|
| Title | 131 I-meta iodobenzylguanidine (131I-MIBG) シンチグラフィーの集計報告 |
|---|
| Subtitle | 原著 |
|---|
| Authors | 和泉元衛*, 掛園布美子*, 永山雄二*, 桐山健*, 横山直方*, 山下俊一*, 森田茂樹*, 平湯秀司*, 久保一郎*, 大財茂*, 岡本純明*, 森本勲夫*, 長瀧重信*, 本保善一郎**, 木下博史**, 計屋慧實**, 中條政敬***, 小嶋正治**** |
|---|
| Authors(kana) | |
|---|
| Organization | *長崎大学医学部第一内科, **放射線科, ***鹿児島大学医学部放射線科, ****九州大学薬学部 |
|---|
| Journal | 核医学 |
|---|
| Volume | 23 |
|---|
| Number | 2 |
|---|
| Page | 145-152 |
|---|
| Year/Month | 1986/2 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」最近Beierwaltesらがノルアドレナリンの誘導体131I-meta iodobenzylguanidine (131I-MIBG, Fig. 1)を用いた褐色細胞腫のシンチグラフィーを報告し, その後このシンチグラフィーが臨床的に非常に有用であると報告されている. 著者らは入院中のSipple症候群の患者の再手術適応には131I-MIBGによる検査が不可欠であったため, 少量の131I-MIBGを合成して検査したところ非常に良好な結果を得た. その結果を発表したところ日本各地から問い合わせがあり, 依頼に応じて各施設に発送していたが, 現在66施設から261例の結果の報告を頂いたのでまとめて報告した. 褐色細胞腫75例中69例(92%)に, またSipple症候群8例全例(100%)に腫瘍に一致して131I-MIBGの異常集積がみられた. 神経芽細胞腫は再発例等含め, 15例中10例(66.7%)に131I-MIBGが取り込まれた. 甲状腺髄様癌はSipple症候群, 再発例等含め12例中6例(50%)に131I-MIBGが取り込まれた. 一方, 他の高血圧患者61例全例に131I-MIBGの取り込みはみられなかった. 以上の結果から, 131I-MIBGシンチグラフィーは褐色細胞腫のみならず, 神経芽細胞腫, 甲状腺髄様癌のすぐれた局在診断法であることが判明した. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | Pheochromocytoma, Medullary thyroid carcinoma, Neuroblastoma, 131I-MIBG scintigraphy. |
|---|
| English |
|---|
| Title | Clinical Applications of 131I-Meta Iodobenzylguanidine (131I-MIBG) Scintigraphy in Japan |
|---|
| Subtitle | Original Articles |
|---|
| Authors | Motomori IZUMI*, Fumiko KAKEZONO*, Yuji NAGAYAMA*, Takeshi KIRIYAMA*, Naokata YOKOYAMA*, Shunichi YAMASHITA*, Shigeki MORITA*, Hideji HIRAYU*, Ichiro KIBO*, Shigeru OHTAKARA*, Sumiaki OKAMOTO*, Isao MORIMOTO*, Shigenobu NAGATAKI*, Zenichiro HONPO**, Masataka NAKAJYO***, Masaharu KOJIMA**** |
|---|
| Authors(kana) | |
|---|
| Organization | *The First Department of Internal Medicine, **Department of Radiology, Nagasaki University School of Medicine, ***Radiology, Faculty of Medicine, Kagoshima University, ****Faculty of Pharmacology, Kyushu University |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 23 |
|---|
| Number | 2 |
|---|
| Page | 145-152 |
|---|
| Year/Month | 1986/2 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | Since Beierwaltes et al initially described a scintigraphy of pheochromocytomas using 131I-meta iodobenzylguanidine (131I-MIBG), it has subsequently been reported that 131I-MIBG scintigraphy is useful for localization of pheochromocytomas. We had a patient with Sipple's syndrome who had pulmonary metastases and persistent hypertension after removal of a pheochromocytoma of an adrenal. 131I-MIBG scintigraphy was performed on this patient and the pulmonary metastases were subsequently found to be malignant pheochromocytoma. Since the time this case was reported, we have received numerous requests for 131I-MIBG from many places throughout Japan. We have sent 131I-MIBG in response to these requests and 131I-MIBG scintigraphy has been performed on 261 patients at 66 different locations. There were 75 patients with pheochromocytoma and 69 (92%) showed an abnormal accumulation of 131I-MIBG in the tumor. All 8 Sipple's syndrome patients (100%) had positive 131I-MIBG scintigrams. Positive scintigrams were observed in 10 of 15 patients (66.7%) with neuroblastoma, and in 6 of 12 patients (50%) who had medullary carcinoma of the thyroid. On the other hand, 61 hypertensive patients without clinical or biochemical manifestations of pheochromocytoma showed no abnormal accumulation of 131I-MIBG, so it appeard that there were no false negative scintigrams. These results indicate that 131I-MIBG scintigraphy is clinically useful for the localization of not only pheochromocytomas but also for neuroblastomas and medullary carcinomas. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | Pheochromocytoma, Medullary thyroid carcinoma, Neuroblastoma, 131I-MIBG scintigraphy. |
|---|